Literature DB >> 16731908

Mutations in influenza virus M1 CCHH, the putative zinc finger motif, cause attenuation in mice and protect mice against lethal influenza virus infection.

Eric Ka-Wai Hui1, Donald F Smee, Min-Hui Wong, Debi P Nayak.   

Abstract

Mutations in CCHH, the putative zinc finger motif, apparently do not play an important role in virus replication in MDCK cells in culture (E. K.-W. Hui, K. Ralston, A. K. Judd, and D. P. Nayak, J. Gen. Virol. 84:3105-3113, 2003). In this report, however, we demonstrate that the CCHH motif plays a critical role in virulence in mice and that some CCHH mutants are highly attenuated in BALB/c mice. Some of the mutant viruses replicated the least in mice lungs, induced little or no lung lesions, and caused highly reduced morbidity and mortality. Furthermore, growth patterns of mutant viruses in different cell lines (MDCK, MLE12, 3LL, A549, and 293T) varied. Mutant viruses that were attenuated in mice also grew poorly in mouse and human cells in culture. However, wild-type (WT) and all mutant viruses replicated to the same titer in MDCK (canine) cells or embryonated chicken eggs. Attenuation in mice correlated with reduced growth in mouse cells in culture, suggesting that potential attenuation in a given host can be predicted from the growth characteristics of the virus in cultured cells (preferably lung cells) from the same species. In challenge experiments, mice immunized by infection with attenuated mutant viruses were fully protected from lethal challenge with WT virus. In summary, the replication and attenuating properties of these mutants suggest that the CCHH motif provides a critical determinant for virulence in mouse and that mutations in the CCHH motif yield potential vaccine candidates for the development of live species-specific attenuated influenza virus vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731908      PMCID: PMC1472591          DOI: 10.1128/JVI.02729-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Influenza virus assembly and budding at the viral budozone.

Authors:  Anthony P Schmitt; Robert A Lamb
Journal:  Adv Virus Res       Date:  2005       Impact factor: 9.937

2.  YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42.

Authors:  Eric Ka-Wai Hui; Subrata Barman; Dominic Ho-Ping Tang; Bryan France; Debi P Nayak
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Structure of influenza virus ribonucleoprotein particles. II. Purified RNA-free influenza virus ribonucleoprotein forms structures that are indistinguishable from the intact influenza virus ribonucleoprotein particles.

Authors:  R W Ruigrok; F Baudin
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

4.  Characterization of the reconstructed 1918 Spanish influenza pandemic virus.

Authors:  Terrence M Tumpey; Christopher F Basler; Patricia V Aguilar; Hui Zeng; Alicia Solórzano; David E Swayne; Nancy J Cox; Jacqueline M Katz; Jeffery K Taubenberger; Peter Palese; Adolfo García-Sastre
Journal:  Science       Date:  2005-10-07       Impact factor: 47.728

Review 5.  The factors of virulence of influenza a virus.

Authors:  T Fislová; F Kostolanský
Journal:  Acta Virol       Date:  2005       Impact factor: 1.162

6.  In vivo anti-influenza virus activity of a zinc finger peptide.

Authors:  A K Judd; A Sanchez; D J Bucher; J H Huffman; K Bailey; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins.

Authors:  M Bui; G Whittaker; A Helenius
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Antiviral activity of influenza virus M1 zinc finger peptides.

Authors:  E H Nasser; A K Judd; A Sanchez; D Anastasiou; D J Bucher
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Cascade of fever production in mice infected with influenza virus.

Authors:  M Kurokawa; M Imakita; C A Kumeda; K Shiraki
Journal:  J Med Virol       Date:  1996-10       Impact factor: 2.327

Review 10.  Role of apoptosis and cytokines in influenza virus morbidity.

Authors:  Edward W A Brydon; Susan J Morris; Clive Sweet
Journal:  FEMS Microbiol Rev       Date:  2004-12-24       Impact factor: 16.408

View more
  6 in total

1.  Identification of amino acid substitutions in avian influenza virus (H5N1) matrix protein 1 by using nanoelectrospray MS and MS/MS.

Authors:  Ning Liu; Wenjun Song; Kim-Chung Lee; Pui Wang; Honglin Chen; Zongwei Cai
Journal:  J Am Soc Mass Spectrom       Date:  2008-10-18       Impact factor: 3.109

2.  In vitro and in vivo replication of influenza A H1N1 WSN33 viruses with different M1 proteins.

Authors:  Zhiguang Ran; Ying Chen; Huigang Shen; Xiaoxiao Xiang; Qinfang Liu; Bhupinder Bawa; Wenbao Qi; Laihua Zhu; Alan Young; Juergen Richt; Wenjun Ma; Feng Li
Journal:  J Gen Virol       Date:  2012-12-19       Impact factor: 3.891

3.  Combination therapy of zinc and trimethoprim inhibits infection of influenza A virus in chick embryo.

Authors:  Magdi H El Habbal
Journal:  Virol J       Date:  2021-06-03       Impact factor: 4.099

4.  Alteration of protein levels during influenza virus H1N1 infection in host cells: a proteomic survey of host and virus reveals differential dynamics.

Authors:  Susann Kummer; Max Flöttmann; Björn Schwanhäusser; Christian Sieben; Michael Veit; Matthias Selbach; Edda Klipp; Andreas Herrmann
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

5.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

6.  The potential of putative zinc-binding motifs of haemagglutinin (HA) protein for categorization and prediction of pathogenicity of H5 subtypes of avian influenza virus.

Authors:  Issa A Muraina; Clement A Meseko; Folorunso O Fasina
Journal:  Med Hypotheses       Date:  2020-05-30       Impact factor: 1.538

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.